TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39163971
Drug: Sucrose syrup
Normalized name: sucrose syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose syrup
Study: 39163972
Drug: Total polyphenol
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total polyphenol intake (∼914 mg/1000 kcal/d)
Study: 39164041
Drug: Secondary cytoreductive
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary cytoreductive surgery followed by platinum-based chemotherapy plus or minus bevacizumab
Study: 39164041
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy plus or minus bevacizumab alone
Study: 39164067
Drug: apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: apremilast 30 mg two times per day
Study: 39164407
Drug: Bosutinib (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib (starting dose: 500 mg QD)
Study: 39164518
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor pathway inhibitors (ARPIs)
Study: 39164613
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injections (TEI)
Study: 39164673
Drug: 10-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-valent pneumococcal conjugate vaccine (PCV10)
Study: 39164808
Drug: 7-day vonoprazan-based
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 7-day vonoprazan-based triple therapy with high-dose amoxicillin (VAC-7)
Study: 39164808
Drug: 14-day extended
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14-day extended sequential therapy (S-14)
Study: 39164933
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) - 25 weekly sessions including behavioural activation, behaviour management, interventions for the caregiver, reminiscence, couples counselling, and cognitive restructuring
Study: 39165373
Drug: Evening LAMA
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening LAMA administration
Study: 39165373
Drug: Morning LAMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning LAMA administration
Study: 39166425
Drug: SHR-2004 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-2004 (0.1, 0.3, or 1.0 mg/kg) administered intravenously (i.v.)
Study: 39166425
Drug: SHR-2004 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-2004 (0.5, 1.0, 3.0, or 4.5 mg/kg) administered subcutaneously (s.c.)
Study: 39166750
Drug: Higher hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher hepatic glucose production (HGP-insulin)
Study: 39167148
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet of selvigaltin under fasted conditions
Study: 39167148
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet of selvigaltin under fed conditions
Study: 39167148
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule of selvigaltin under fasted conditions
Study: 39167148
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments of selvigaltin (tablet and capsule)
Study: 39167305
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel with AGS
Study: 39167348
Drug: Venetoclax treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax treatment
Study: 39167348
Drug: Venetoclax treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax treatment with concomitant rituximab
Study: 39167348
Drug: Venetoclax treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax treatment with 1 prior line of therapy
Study: 39167348
Drug: Venetoclax treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax treatment with ≥ 2 prior lines of therapy
Study: 39167366
Drug: Zasocitinib 2
Normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zasocitinib 2 mg
Study: 39167366
Drug: Zasocitinib 5
Normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zasocitinib 5 mg
Study: 39167366
Drug: Zasocitinib 15
Normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zasocitinib 15 mg
Study: 39167366
Drug: Zasocitinib 30
Normalized name: Tasocitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zasocitinib 30 mg
Study: 39167366
Drug: Zasocitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zasocitinib (all doses)
Study: 39167421
Drug: CBD (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene)
Study: 39167533
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous PTH (1-34) infusion
Study: 39167741
Drug: Personalized chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized chemotherapy based on tumor marker decline
Study: 39167748
Drug: Migraine frequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine frequency less than monthly
Study: 39167807
Drug: Belzutifan (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belzutifan (120 mg orally once daily)
Study: 39168564
Drug: Olpasiran 75
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 75 mg Q12W
Study: 39168564
Drug: Olpasiran 225
Normalized name: Olpasiran
DrugBank: Olpasiran (DB19001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olpasiran 225 mg Q12W
Study: 39169058
Drug: Immune killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immune killer cells (IKC) infusion weekly for 24 weeks
Study: 39169058
Drug: Immune killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immune killer cells (IKC) infusion
Study: 39169095
Drug: Invisalign treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invisalign treatment with upper and lower aligners (average treatment time of 18 ± 6 months)
Study: 39169298
Drug: 5-day postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day postoperative antibiotic therapy (piperacillin/tazobactam)
Study: 39169349
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment group using the Dialogue Support
Study: 39169349
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment group using the Dialogue Support
Study: 39169353
Drug: Soymilk (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk (500 mL daily, 22 g soy protein, 17.2 g or 6.9 g/250 mL added sugars)
Study: 39169699
Drug: PEERS® program
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEERS® program (treatment group, n=10)
Study: 39169827
Drug: DS-7011a (anti-TLR7
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-7011a (anti-TLR7 monoclonal antibody) administered intravenously (IV) and subcutaneously (SC) in a 6:2 ratio against placebo.
Study: 39169827
Drug: DS-7011a (anti-TLR7
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-7011a (anti-TLR7 monoclonal antibody) administered IV and SC.
Study: 39170110
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg esketamine + PCEA
Study: 39170110
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg esketamine + PCIA
Study: 39171074
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nonpharmacological interventions including a daily dose of both investigational products and dietary counseling on increasing dietary fiber.
Study: 39171074
Drug: Daily dose
Normalized name: LENVIMA 8mg Daily Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of both investigational drugs only.
Study: 39171394
Drug: Intravenous acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acetazolamide
Study: 39172479
Drug: Olaparib, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib, 300 mg by mouth twice daily until PSA doubling, clinical or radiographic progression, or unacceptable toxic effects.
Study: 39172730
Drug: ARX517 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARX517 (a site-specific stable PSMA-targeted antibody-drug conjugate)
Study: 39173075
Drug: TAK-003 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 vaccine (two doses administered 3 months apart)
Study: 39173075
Drug: TAK-003 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 vaccine (baseline vaccination scenario)
Study: 39173075
Drug: TAK-003 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 vaccine (extreme high scenario)
Study: 39173088
Drug: CEE-alone (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE-alone (0.625 mg daily)
Study: 39173088
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA (0.625 mg CEE plus 2.5 mg MPA daily)
Study: 39173175
Drug: Lumacaftor/Ivacaftor treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor/Ivacaftor treatment
Study: 39173229
Drug: Plinabulin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plinabulin (30 mg/m²), nivolumab (1 mg/kg), ipilimumab (3 mg/kg)
Study: 39173560
Drug: Pill counts
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill counts (PC)
Study: 39173703
Drug: Preconception vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconception vitamin D status and bioavailability
Study: 39174285
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care treatment for LTBI
Study: 39174285
Drug: Secondary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary care treatment for LTBI
Study: 39174449
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) plus progressive muscle relaxation (PMR) intervention
Study: 39174542
Drug: Sintilimab (anti-PD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT), and granulocyte-macrophage colony-stimulating factor (GM-CSF)
Study: 39174857
Drug: Delayed-release form
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release form containing 1.9 mg melatonin, 10 mg zinc, and 200 mg lemon balm extract
Study: 39174857
Drug: Delayed-release form
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release form
Study: 39174958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 native implants)
Study: 39175342
Drug: Day-2-group (warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-2-group (warfarin started on day 2 after CS)
Study: 39175342
Drug: Day-5-group (warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-5-group (warfarin started on day 5 after CS)
Study: 39175480
Drug: CHOPX (CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOPX (CHOP plus targeted agents)
Study: 39175547
Drug: Fospropofol disodium
Normalized name: Fospropofol disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fospropofol disodium (6.5 mg/kg initial bolus, 1.6 mg/kg supplemental as needed)
Study: 39175547
Drug: Propofol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.5 mg/kg initial bolus, 0.5 mg/kg supplemental as needed)
Study: 39176240
Drug: Add-on low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on low dose Astragalus membranaceus (AM) for 24 weeks
Study: 39176240
Drug: Add-on high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on high dose Astragalus membranaceus (AM) for 24 weeks
Study: 39176240
Drug: Add-on low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on low dose Astragalus membranaceus (AM)
Study: 39176240
Drug: Add-on high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on high dose Astragalus membranaceus (AM)
Study: 39176240
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (low dose AM, high dose AM, routine care)
Study: 39178168
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy dressings (Prevena™ and PICO™)
Study: 39179206
Drug: FIBCRO (sourdough-leavened
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIBCRO (sourdough-leavened croissant enriched with dietary fibers, 4.8 g/100 g)
Study: 39179206
Drug: CONCRO (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONCRO (control croissant, dietary fibers 1.3 g/100 g)
Study: 39179207
Drug: Synbiotic (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic (400 mg/100 mL GOS and L. reuteri DSM 17938)
Study: 39179255
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) including anti-PD-1 (79.3%), anti-PD-L1 (17.9%), combination of anti-PD-1 and anti-CTLA-4 (2.1%), anti-PD-1 with anti-VEGFR (0.7%)
Study: 39179638
Drug: S-MDMA (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-MDMA (125 mg)
Study: 39179638
Drug: R-MDMA (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-MDMA (125 mg and 250 mg)
Study: 39179638
Drug: R-MDMA (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-MDMA (125 mg)
Study: 39179638
Drug: R-MDMA (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-MDMA (250 mg)
Study: 39179855
Drug: CyberRwanda facilitated
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyberRwanda facilitated arm (peer-led clubs plus tablet access)
Study: 39179855
Drug: CyberRwanda self-service
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CyberRwanda self-service arm (self-guided access on tablets)
Study: 39179863
Drug: Tislelizumab combined
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab combined with cisplatin and 5-fluorouracil (induction therapy)
Study: 39180187
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with endocrine therapy (bicalutamide for 4 weeks and abiraterone for 2 years)
Study: 39180325
Drug: PF-06425090 vaccine
Normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06425090 vaccine (3 doses at 0, 1, and 6 months)
Study: 39180326
Drug: Fecal microbiota,
Normalized name: fecal microbiota, live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota, live-jslm (REBYOTA) administered rectally within 24-72h of antibiotic completion.
Study: 39180326
Drug: Fecal microbiota,
Normalized name: fecal microbiota, live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota, live-jslm (REBYOTA) administered rectally.
Study: 39181037
Drug: EPA/DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA/DHA supplementation (2.0 g daily for 10 weeks)
Study: 39181037
Drug: HMB +
Normalized name: Hydroxymethylbutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB + EPA/DHA supplementation (3.0 g Ca-HMB daily for 10 weeks)
Study: 39181206
Drug: Lutein/zeaxanthin (LZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein/zeaxanthin (LZ) intake (≥2 mg/day compared with <2)
Study: 39181206
Drug: Higher intake
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher intake of ω-3 fatty acids (≥0.7 g/week compared with <0.7)
Study: 39181422
Drug: Canakinumab (CAN)
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab (CAN) 3 mg/kg
Study: 39182045
Drug: suPAR >
Approvals — FDA: no, EMA: no, PMDA: no
Description: suPAR > 5.1 ng/mL
Study: 39182045
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of suPAR > 9.8 ng/mL, BMI < 29.3 kg/m2, PSI > 106.5
Study: 39182315
Drug: Vaccine Declined
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine Declined
Study: 39182330
Drug: Alirocumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab plus statin therapy
Study: 39182487
Drug: IV thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV thrombolysis (IVT) in patients on oral anticoagulation
Study: 39182487
Drug: IV thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV thrombolysis (IVT) in patients without oral anticoagulation
Study: 39182655
Drug: Sirukumab 5
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 5 mg/kg IV on Day 1 plus standard of care
Study: 39184998
Drug: AGuIX nanoparticles
Normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AGuIX nanoparticles (4 injections at 50, 75, and 100 mg/kg) with radiotherapy (RT 60 Gy) and concomitant/adjuvant temozolomide (TMZ)
Study: 39184998
Drug: AGuIX nanoparticles
Normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AGuIX nanoparticles (100 mg/kg)
Study: 39185596
Drug: SLFN11-positive tumors
Normalized name: HUMAN BREAST TUMOR CELL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLFN11-positive tumors (e.g., mesotheliomas, clear cell renal cell carcinomas, small cell lung cancers, squamous cell carcinomas of the tonsil and larynx, ovarian serous carcinomas)
Study: 39185596
Drug: SLFN11-negative tumors
Normalized name: HUMAN BREAST TUMOR CELL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLFN11-negative tumors (e.g., hepatocellular, prostatic, colorectal, breast cancers)
Study: 39186143
Drug: Add-on dupilumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on dupilumab therapy
Study: 39186143
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background therapy alone
Study: 39186315
Drug: Any other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any other therapy
Study: 39186326
Drug: Bone-anchored hearing
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-anchored hearing implant surgery using the MONO procedure
Study: 39186380
Drug: Adipose-Derived Mesenchymal
Normalized name: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins
DrugBank: Adipose-Derived Mesenchymal Stem Cells: Autologous or Allogeneic Origins (DB15729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy
Study: 39186770
Drug: Enhanced usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced usual care (single microgrant plus monthly financial literacy education)
Study: 39186770
Drug: Extended microgrants
Normalized name: Extramel microgranules
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended microgrants (enhanced usual care plus monthly microgrants)
Study: 39187401
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg once daily for up to 1 year
Study: 39187595
Drug: anti-TIGIT antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-TIGIT antibody
Study: 39187595
Drug: anti-LAG3 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-LAG3 antibody
Study: 39188412
Drug: Balance chiropractic
Normalized name: Rebalance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balance chiropractic therapy (BCT) for 20 days
Study: 39188940
Drug: Transdiagnostic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic group treatment protocol administered in a blended format
Study: 39188943
Drug: FCN-437c 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c 400 mg
Study: 39188996
Drug: Positron emission
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron emission tomography/computed tomography after intravenous administration of 296 MBq
Study: 39189858
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1200 mg orally twice daily for days 1 to 112
Study: 39189858
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without NAC
Study: 39190445
Drug: Growing engagement
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Growing engagement in therapy
Study: 39190534
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy for CD8-high patients (CD8 ≥15%)
Study: 39191745
Drug: CoronaVac booster
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac booster (CC-C)
Study: 39191745
Drug: CoronaVac (CC-C)
Normalized name: CoronaVac
DrugBank: CoronaVac (DB15806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (CC-C)